LAG3 and melanoma: Several studies have shown the presence of a LAG-3-positive lymphocytic infiltrate in melanoma, laying the basis of a new therapeutic approach aimed at LAG-3/MCH-II binding inhibition (Hemon et al., 2011; Durham et al., 2014).